The medical community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s exhibiting significant efficacy in clinical trials for addressing obesity. Unlike some current weight loss solutions, retatrutide appears to provide a significant substantial los